First head-to-head study in people living with obesity shows tirzepatide results in around 50% more weight loss than semaglutide
A new head-to-head study of tirzepatide versus semaglutide for weight loss in people living with obesity, but not diabetes, shows that over 72 weeks tirzepatide results in an average weight loss of 20.2%, 47% higher than the 13.7% average weight loss for semaglutide. The study, presented at this year’s European Congress on Obesity in Malaga, Spain (11-14 May) and published in NEJM, is by Dr Louis J Aronne, Comprehensive Weight Control Center, Weill Cornell Medicine, New York, New York, USA, and colleagues.